Wave Life Sciences Inc. (WVE)
NASDAQ: WVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
WVE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $504.91M
- EPS (TTM)
- -$1.07
- Dividend yield
- None
- 52-week range
- 2.55 – 21.73
- Day range
- 2.55 – 2.79
- Volume / Avg
- 2.28M / 3.11M
- Beta
- —
- Shares outstanding
- 197.23M
52-week range
WVE stock today
Shares of Wave Life Sciences (WVE) finished lower on Nov 20 at $2.56, a drop of 5.88% or $0.16 per share, versus the S&P 500's 3.70% decline. At this level, WVE sits near the bottom of its 52-week range of $2.55 to $21.73: 88.2% below the high, set on Dec 9, 2025 and 0.6% above the low. WVE is down 84.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 63.7%.
Wave Life Sciences has posted a net loss over the last twelve months (EPS of -$1.07), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Wave Life Sciences
Company profileWave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Paul B. Bolno M.B.A., M.D.
- Headquarters
- Cambridge, MA
- Employees
- 317
- IPO year
- 2015
- Website
- wavelifesciences.com
Financial highlights
Full financialsIn fiscal 2025, Wave Life Sciences generated $42.7 million in revenue, down 60.5% from fiscal 2024, its first annual decline since 2024. Wave Life Sciences reported a net loss of $204.4 million, compared with a loss of $97.0 million a year earlier. Operating margin was -504.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $42.73M | $108.30M | $113.31M | $3.65M | $40.96M |
| Growth | -60.55% | -4.42% | +3005.10% | -91.09% | +104.03% |
| Net income | $-204.38M | $-97.01M | $-57.51M | $-161.82M | $-122.25M |
| EPS (diluted) | $-1.21 | $-0.70 | $-0.54 | $-2.05 | $-2.36 |
Analyst forecast
ForecastConsensus (21 analysts)
strong_buy
Avg. price target
$16.63+549.61%
- Strong buy 2
- Buy 17
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 27, 2026
- EPS actual vs est.
- $-0.30 vs $-0.34
- Surprise
- +11.76%
WVE news
All WVE news- Wave Life Sciences Ltd. Stockholders Approve 11,000,000 Share Increase for Equity Incentive PlanNasdaq
- Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026GlobeNewswire
- Wave Life Sciences to Present at Jefferies Global Healthcare Conference in LondonGlobeNewswire
- Wave: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Wave Life Sciences (WVE) Q3 2026 Earnings Call TranscriptNasdaq
- Wave Life Sciences Ltd. Reports Third Quarter 2026 Financial ResultsNasdaq
- Wave Life Sciences GAAP EPS of -$0.30 beats by $0.03, revenue of $13.16M beats by $8.77MSeeking Alpha
- Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
Wave Life Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALMSAlumis Inc. | 3.96 | -8.54% | $514.09M | vs WVE |
| ZVRAZevra Therapeutics Inc. | 8.76 | -3.42% | $521.26M | vs WVE |
| HELPHelus Pharma Inc. | 6.11 | -9.88% | $487.68M | vs WVE |
| CLYMClimb Bio Inc. | 9.19 | -0.97% | $539.80M | vs WVE |
| EVOEvotec SE ADR | 1.32 | -8.97% | $469.11M | vs WVE |
| MNPRMonopar Therapeutics Inc. | 69.00 | -1.84% | $467.60M | vs WVE |
| CBIOCrescent Biopharma Inc. | 13.00 | +0.70% | $543.21M | vs WVE |
| AVBPArriVent BioPharma Inc. | 10.52 | -6.57% | $544.13M | vs WVE |
Indexes, lists and sector
Wave Life Sciences stock FAQ
What is Wave Life Sciences's stock price today?
WVE last traded at $2.56 as of Nov 20, 4:00 PM EST, down 5.88% on the day. Prices are delayed at least 15 minutes.
Who is Wave Life Sciences's CEO?
Dr. Paul B. Bolno M.B.A., M.D. is the chief executive officer of Wave Life Sciences Inc., which has about 317 employees.
What is the WVE 52-week high?
The 52-week high for WVE is $21.73 and the 52-week low is $2.55. The stock is currently 88.2% below its high.